STEM CELL RESEARCH FOR ALCOHOL-RELATED DISORDERS 

Release Date:  March 13, 2002

RFA:  RFA-AA-02-010

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 (http://www.niaaa.nih.gov)
 
LETTER OF INTENT RECEIPT DATE:  April 15, 2002

APPLICATION RECEIPT DATE:  May 15, 2002

THIS RFA CONTAINS THE FOLLOWING INFORMATION

o Purpose of this RFA
o Research Objectives
o Mechanism(s) of Support 
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements 
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations

PURPOSE OF THIS RFA 

The purpose of this RFA is to foster research on 1) the impact of alcohol 
exposure on embryonic and adult stem cell biology; 2) the capacity of stem 
cells to replace tissues and/or restore function directly at sites of alcohol-
induced organ and fetal damage in animal models; 3) the use of stem cells as a 
tool to further elucidate mechanisms of alcohol dependence and alcohol-related 
pathological conditions, such as brain degeneration, alcoholic liver disease, 
pancreatitis, and fetal alcohol syndrome; and 4) restoration of normal 
function in alcohol-damaged tissues using stem cells in combination with gene 
therapy. 

RESEARCH OBJECTIVES

Background

Long-term alcohol abuse is known to cause pathologies in a number of the 
body's organ systems. Those disorders most commonly associated with chronic 
alcohol consumption include alcoholic liver disease (ALD), pancreatitis, 
cardiovascular disease, endocrine dysfunction, osteoporosis, cancer, and 
immune dysfunction.  Heavy alcohol intake is also associated with structural 
and functional changes in the adult and developing central nervous system, 
manifested by brain atrophy and neurodegeneration, as well as 
neurodevelopmental disorders such as fetal alcohol syndrome.  Brain regions 
most severely affected by chronic alcohol consumption, as well as by prenatal 
alcohol exposure, are the frontal cortex, cerebellum, hippocampus, and the 
hypothalamus.    

Embryonic and adult stem cells offer powerful tools to elucidate mechanisms 
underlying normal biological functions and the mechanisms by which alcohol 
disrupts normal functions in susceptible organs.  They may also prove valuable 
in developing therapeutic approaches for treating alcohol-induced 
physiological impairments and overt organ damage.  Although rapid progress has 
been made in characterizing embryonic and adult stem cells and their capacity 
to proliferate, migrate, differentiate, and integrate into multiple tissues, 
very little is known about how alcohol affects these processes. For example, 
does alcohol exposure alter normal stem cell fate determination and 
plasticity?  Does chronic alcohol consumption alter the number and 
availability of autologous stem cells and their biological properties?  Does 
alcohol exposure alter the biochemical environment of tissues, thus 
interfering with the capacity of stem cells to establish contact, 
differentiate and function in target tissues?  Does alcohol interfere with the 
capacity of endogenous stem cells to limit or repair alcohol-induced pathology 
in various tissues? These are some of the fundamental research questions that 
need to be addressed.  

It now appears that cell fate changes are a natural property of stem cells and 
may be involved in tissue homeostasis and repair of tissue damage.  For 
example, adult neural stem cells have the capacity to express a variety of 
neuronal cell types, and hematopoietic stem cells have been shown to form 
functional liver hepatocytes. Evidence suggests that circulating stem cells 
home to niches within an organ, where signaling factors stimulate 
differentiation into the desired cell types.  The effects of different 
patterns of chronic alcohol exposure on the niche environments essential for 
engrafting and differentiation of stem cells needs further investigation. 
Although more research is needed to improve stem cell isolation techniques, 
use of autologous adult stem cells for tissue-replacement therapy could 
represent a major advantage by avoiding immune rejection.  However, it is 
unclear whether chronic alcohol consumption would also destroy the host's 
natural supply of stem cells and/or alter their capacity to respond to 
cellular signals in target tissues. In liver regeneration, both oval stem 
cells and hematopoietic stem cells are key players; thus, the capacity of 
these cells to regenerate the architecture necessary to support liver function 
after chronic alcohol exposure also needs to be studied.

Stem cells have particularly exciting potential in combination with genetic 
engineering strategies and gene therapy.  Stem cells stably expressing 
transgenes may be used to deliver soluble molecules to specific sites by 
migrating and differentiating into the target tissue. In addition to tissue 
repair, stem cells have the potential to control progression of disease.  For 
example, engrafted stem cells engineered to overexpress proteins in specific 
brain regions potentially could modulate host levels of critical 
neurotransmitters involved in pathological alcohol consumption.  Furthermore, 
transgene expression in a patient's own somatic stem cells should prevent the 
adverse immune responses often seen with adenovirus and other gene therapy 
vectors. Combination therapy is likely to be most useful for certain alcohol-
related disorders where delivery of genes will compensate for impaired 
enzymes, peptides, and neurotransmitters.

Research Objectives and Scope

This RFA solicits research on the application of stem cells to alcohol-
relevant problems.  The use of stem cells derived from any approved source, 
including human embryonic stem cell lines listed in the NIH Human Embryonic 
Stem Cell Registry (see REQUIRED FEDERAL CITATIONS below for additional 
information) is encouraged.  Although some types of clinical research would be 
appropriate for this RFA, clinical trials are outside the scope of the RFA.

Examples of research that would be responsive to this RFA are identified 
below.  These research areas are not intended to be inclusive or restrictive.

o  Studies on the effects of alcohol on in vivo and ex vivo stem cell 
viability and differentiation into specific cell types including neurons,glial 
cells, liver cells, pancreatic cells, cardiomyocytes, etc.

o  Biochemical and physiological studies examining the capacity of stem cells 
to integrate with host tissues and to restore impaired tissue function under 
conditions of chronic alcohol exposure.

o  Studies to determine the effects of alcohol dose and exposure pattern on 
the long-term fate of transplanted stem cell-derived populations in animal 
models of alcohol-induced tissue injury including brain and liver damage.

o  Studies to assess the functional integrity of autologous stem cells in  
animal models of prenatal, adolescent, and adult alcohol exposure.

o  Studies to determine the effectiveness of stem cells engineered to 
overexpress candidate genes/proteins to offset/reverse neural maladaptive 
responses to alcohol, such as tolerance, dependence, craving, and withdrawal.

o  Development, in animal models, of stem cell transplantation and combination 
stem cell/gene therapy approaches to protect against or prevent alcohol-
induced tissue damage, or hasten repair of integral processes that are 
sensitive to alcohol.

MECHANISM OF SUPPORT

This RFA will use NIH research project grant (R01), NIAAA 
exploratory/developmental grant (R21), and NIAAA small grant (R03) award 
mechanisms. As an applicant you will be solely responsible for planning, 
directing, and executing the proposed project. Exploratory/developmental 
grants (R21) are limited to three years for up to $100,000 per year for direct 
costs.  (See PA-99-131, "NIAAA Exploratory/Developmental Grant Program," 
http://grants.nih.gov/grants/guide/pa-files/PA-99-131.html, for a complete 
description of the R21 mechanism.) Small grants (R03) are limited to two years 
for up to $50,000 per year for direct costs.  (See PAR-99-098, "NIAAA Small 
Grant Program," http://grants.nih.gov/grants/guide/pa-files/PAR-99-098.html, 
for a complete description of the R03 mechanism.) This RFA is a one-time 
solicitation.  Future unsolicited, competing applications based on this 
project will compete with all investigator-initiated applications and will be 
reviewed according to the customary peer review procedures. 

This RFA uses just-in-time concepts.  It also uses the modular as well as the 
non-modular budgeting formats (see 
http://grants.nih.gov/grants/funding/modular/modular.htm).  Specifically, if 
you are submitting an application with direct costs in each year of $300,000 
or less, use the modular format.  Otherwise follow the instructions for non-
modular research grant applications.

FUNDS AVAILABLE 

The NIAAA intends to commit approximately $2 million in FY 2002 to fund six to 
eight new and/or competitive continuation grants in response to this RFA. An 
applicant may request a project period of up to five years and a budget for 
direct costs of up to $300,000 per year, using the R01 support mechanism.  An 
applicant may request a shorter project period and lesser amount of support, 
using the R03 or R21 mechanism, as described above.  Because the nature and 
scope of the proposed research will vary from application to application, it 
is anticipated that the size and duration of each award will also vary. 
Although the financial plans of the NIAAA provide support for this program, 
awards pursuant to this RFA are contingent upon the availability of funds and 
the receipt of a sufficient number of meritorious applications. At this time, 
it is not known if this RFA will be reissued.

ELIGIBLE INSTITUTIONS
 
You may submit an application if your institution has any of the following 
characteristics: 
	
o For-profit or non-profit organizations 
o Public or private institutions, such as universities, colleges, hospitals, 
and laboratories 
o Units of State and local governments
o Eligible agencies of the Federal government  
o Domestic or foreign (only domestic organizations are eligible for the R03 
mechanism)
 
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS   

Any individual with the skills, knowledge, and resources necessary to carry 
out the proposed research is invited to work with their institution to develop 
an application for support.  Individuals from underrepresented racial and 
ethnic groups as well as individuals with disabilities are always encouraged 
to apply for NIH programs.   

SPECIAL REQUIREMENTS

Investigators wishing to obtain support for research relevant to this RFA who 
lack expertise in alcohol research are encouraged to collaborate with 
investigators who are experienced in alcohol research, insofar as such 
experience will prove essential for proper study design and data analysis.  
Investigators desiring to establish such collaborations are encouraged to 
contact the individuals listed under WHERE TO SEND INQUIRIES below.  
Investigators who lack expertise in stem cell research should seek 
collaboration with researchers who are familiar with aspects of stem cell 
research that are relevant to the proposed research.

Awardees will be expected to attend one joint meeting every two years in or 
near Washington, DC, in order to review progress and exchange information.  
Sufficient funds to support attendance at these meetings should be included in 
the budget.

WHERE TO SEND INQUIRIES

We encourage inquiries concerning this RFA and welcome the opportunity to 
answer questions from potential applicants.  Inquiries may fall into three 
areas:  scientific/research, peer review, and financial or grants management 
issues:

o Direct your questions about scientific/research issues to:

Lisa Neuhold, Ph.D.
Neuroscience and Genetics Programs
Neurosciences and Behavioral Research Branch
National Institute on Alcohol Abuse and Alcoholism 
6000 Executive Boulevard, Suite 402, MSC 7003
Bethesda, MD  20892-7003
Telephone:  (301) 594-6228  
FAX: (301) 594-0673
Email: lneuhold@willco.niaaa.nih.gov

Laurie Foudin, Ph.D.
Tissue Injury and Fetal Alcohol Research Programs
Biomedical Research Branch
National Institute on Alcohol Abuse and Alcoholism
6000 Executive Boulevard, Suite 402, MSC 7003
Bethesda, MD 20892-7003
Telephone:  (301) 443-9812
FAX:  (301) 594-0673
Email:  Lfoudin@nih.gov

o Direct your questions about peer review issues to:

Extramural Project Review Branch 
National Institute on Alcohol Abuse and Alcoholism 
6000 Executive Boulevard, Room 409, MSC 7003 
Bethesda, MD 20892-7003 
Telephone: (301) 443-4375 

o Direct your questions about financial or grants management matters to:

Ms. Judy Simons 
Grants Management Branch
National Institute on Alcohol Abuse and Alcoholism
6000 Executive Boulevard, Suite 504, MSC 7003 
Bethesda, MD 20892-7003 
Telephone: (301) 443-4704
FAX (301) 443-3891 
Email:  jsimons@willco.niaaa.nih.gov 

LETTER OF INTENT

Prospective applicants are asked to submit a letter of intent that includes 
the following information:

o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel 
o Participating institutions
o Number and title of this RFA 

Although a letter of intent is not required, is not binding, and does not 
enter into the review of a subsequent application, the information that it 
contains allows NIAAA staff to estimate the potential review workload and plan 
the review.
 
The letter of intent is to be sent by the date listed at the beginning of this 
document.  The letter of intent should be sent to:

RFA-AA-02-010
Extramural Project Review Branch 
National Institute on Alcohol Abuse and Alcoholism 
6000 Executive Boulevard, Room 409, MSC 7003 
Bethesda, MD 20892-7003 
Rockville, MD 20852 (for express/courier service) 
FAX: (301) 443-6077

SUBMITTING AN APPLICATION

Applications must be prepared using the PHS 398 research grant application 
instructions and forms (rev. 5/2001).  The PHS 398 is available at 
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive 
format.  For further assistance contact GrantsInfo, Telephone (301) 435-0714, 
Email: GrantsInfo@nih.gov.
 
SUPPLEMENTAL INSTRUCTIONS:  Applicants who plan to submit a small grant (R03) 
application must follow the instructions provided in PAR-99-098, "NIAAA Small 
Grant Program," http://grants.nih.gov/grants/guide/pa-files/PAR-99-098.html.
 
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS: Applications requesting 
up to $300,000 per year in direct costs must be submitted in a modular grant 
format.  The modular grant format simplifies the preparation of the budget in 
these applications by limiting the level of budgetary detail.  Applicants 
request direct costs in $25,000 modules.  Section C of the research grant 
application instructions for the PHS 398 (rev. 5/2001) at 
http://grants.nih.gov/grants/funding/phs398/phs398.html includes step-by-step 
guidance for preparing modular grants.  Additional information on modular 
grants is available at 
http://grants.nih.gov/grants/funding/modular/modular.htm.

USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001) 
application form must be affixed to the bottom of the face page of the 
application.  Type the RFA number on the label.  Failure to use this label 
could result in delayed processing of the application such that it may not 
reach the review committee in time for review.  In addition, the RFA title and 
number must be typed on line 2 of the face page of the application form and 
the YES box must be marked. The RFA label is also available at: 
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf.
 
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of 
the application, including the Checklist, and three signed, photocopies, in 
one package to:
 
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)
 
At the time of submission, two additional copies of the application must be 
sent to:

AA-02-010
Extramural Project Review Branch 
National Institute on Alcohol Abuse and Alcoholism 
6000 Executive Boulevard, Room 409, MSC 7003 
Bethesda, MD 20892-7003 
Rockville, MD 20852 (for express/courier service) 

APPLICATION PROCESSING: Applications must be received by the application 
receipt date listed in the heading of this RFA.  If an application is received 
after that date, it will be returned to the applicant without review.
 
The Center for Scientific Review (CSR) will not accept any application in 
response to this RFA that is essentially the same as one currently pending 
initial review, unless the applicant withdraws the pending application.  The 
CSR will not accept any application that is essentially the same as one 
already reviewed. This does not preclude the submission of substantial 
revisions of applications already reviewed, but such applications must include 
an Introduction addressing the previous critique.

PEER REVIEW PROCESS  
 
Upon receipt, applications will be reviewed for completeness by the CSR and 
responsiveness by the NIAAA. Incomplete applications will be returned to the 
applicant without further consideration.  And, if the application is not 
responsive to the RFA, CSR staff may contact the applicant to determine 
whether to return the application to the applicant or submit it for review in 
competition with unsolicited applications at the next appropriate NIH review 
cycle.

Applications that are complete and responsive to the RFA will be evaluated for 
scientific and technical merit by an appropriate peer review group convened by 
the NIAAA in accordance with the review criteria stated below.  As part of the 
initial merit review, all applications will:

o Receive a written critique
o Undergo a process in which only those applications deemed to have the 
highest scientific merit, generally the top half of the applications under 
review, will be discussed and assigned a priority score
o Receive a second level review by the NIAAA National Advisory Council on 
Alcohol Abuse and Alcoholism. 
 
REVIEW CRITERIA

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments, reviewers will be asked to discuss the following aspects 
of your application in order to judge the likelihood that the proposed 
research will have a substantial impact on the pursuit of these goals: 

o Significance 
o Approach 
o Innovation
o Investigator
o Environment
  
The scientific review group will address and consider each of these criteria 
in assigning your application's overall score, weighting them as appropriate 
for each application.  Your application does not need to be strong in all 
categories to be judged likely to have major scientific impact and thus 
deserve a high priority score.  For example, you may propose to carry out 
important work that by its nature is not innovative but is essential to move a 
field forward.

(1) SIGNIFICANCE:  Does your study address an important problem? If the aims 
of your application are achieved, how do they advance scientific knowledge?  
What will be the effect of these studies on the concepts or methods that drive 
this field?

(2) APPROACH:  Are the conceptual framework, design, methods, and analyses 
adequately developed, well integrated, and appropriate to the aims of the 
project?  Do you acknowledge potential problem areas and consider alternative 
tactics?

(3) INNOVATION:  Does your project employ novel concepts, approaches or 
methods? Are the aims original and innovative?  Does your project challenge 
existing paradigms or develop new methodologies or technologies?

(4) INVESTIGATOR: Are you appropriately trained and well suited to carry out 
this work?  Is the work proposed appropriate to your experience level as the 
principal investigator and to that of other researchers (if any)?

(5) ENVIRONMENT:  Does the scientific environment in which your work will be 
done contribute to the probability of success?  Do the proposed experiments 
take advantage of unique features of the scientific environment or employ 
useful collaborative arrangements?  Is there evidence of institutional 
support?

ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, your 
application will also be reviewed with respect to the following:

o PROTECTIONS:  The adequacy of the proposed protection for humans, animals, 
or the environment, to the extent they may be adversely affected by the 
project proposed in the application.

o INCLUSION:  The adequacy of plans to include subjects from both genders, all 
racial and ethnic groups (and subgroups), and children as appropriate for the 
scientific goals of the research.  Plans for the recruitment and retention of 
subjects will also be evaluated. (See Inclusion Criteria included in the 
section on Federal Citations, below)

o BUDGET:  The reasonableness of the proposed budget and the requested period 
of support in relation to the proposed research.

o OTHER REVIEW CRITERIA:  Additional considerations pertinent to the review of 
Exploratory/Developmental Grant (R21) and Small Grant (R03) applications 
include: 1) Pilot/feasibility studies contain little or no preliminary data.  
Review should focus on whether the rationale for the study is well developed 
and whether the proposed research is likely to generate data that will lead to 
a regular research project grant or full-scale clinical trial.  Adequate 
justification for the work may be provided through literature citations, data 
from other sources, or investigator-generated data.  2) Because the research 
plan of R03 applications is limited to ten pages, these applications may not 
have the level of detail or extensive discussion normally found in an R01 
application.  Review emphasis should be placed on conceptual framework and 
general approach to the problem, with less emphasis on methodological details.

RECEIPT AND REVIEW SCHEDULE

Letter of Intent Receipt Date:  April 15, 2002 
Application Receipt Date:  May 15, 2002
Peer Review Date:  July-August 2002
Council Review:  September 2002
Earliest Anticipated Start Date:  September 28, 2002

AWARD CRITERIA

Award criteria that will be used to make award decisions include:

o  scientific merit (as determined by peer review)
o  availability of funds
o  programmatic priorities.

REQUIRED FEDERAL CITATIONS 

INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of 
the NIH that women and members of minority groups and their sub-populations 
must be included in all NIH-supported clinical research projects unless a 
clear and compelling justification is provided indicating that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of the 
research. This policy results from the NIH Revitalization Act of 1993 (Section 
492B of Public Law 103-43).

All investigators proposing clinical research should read the AMENDMENT "NIH 
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical 
Research - Amended, October, 2001," published in the NIH Guide for Grants and 
Contracts on October 9, 2001 (http://grants.nih.gov/grants/guide/notice-
files/NOT-OD-02-001.html); a complete copy of the updated Guidelines are 
available at 
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm
.   The amended policy incorporates: the use of an NIH definition of clinical 
research; updated racial and ethnic categories in compliance with the new OMB 
standards; clarification of language governing NIH-defined Phase III clinical 
trials consistent with the new PHS Form 398; and updated roles and 
responsibilities of NIH staff and the extramural community.  The policy 
continues to require for all NIH-defined Phase III clinical trials that: a) 
all applications or proposals and/or protocols must provide a description of 
plans to conduct analyses, as appropriate, to address differences by 
sex/gender and/or racial/ethnic groups, including subgroups if applicable; 
and b) investigators must report annual accrual and progress in conducting 
analyses, as appropriate, by sex/gender and/or racial/ethnic group 
differences.

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:  
The NIH maintains a policy that children (i.e., individuals under the age of 
21) must be included in all human subjects research, conducted or supported by 
the NIH, unless there are scientific and ethical reasons not to include them. 
This policy applies to all initial (Type 1) applications submitted for receipt 
dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the inclusion of children as participants in 
research involving human subjects that is available at 
http://grants.nih.gov/grants/funding/children/children.htm. 

REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS:  NIH 
policy requires education on the protection of human subject participants for 
all investigators submitting NIH proposals for research involving human 
subjects.  You will find this policy announcement in the NIH Guide for Grants 
and Contracts Announcement, dated June 5, 2000, at 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on 
hESCs can be found at http://grants.nih.gov/grants/stem_cells.htm and at 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.  Only 
research using hESC lines that are registered in the NIH Human Embryonic Stem 
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov).   
It is the responsibility of the applicant to provide the official NIH 
identifier(s)for the hESC line(s)to be used in the proposed research.  
Applications that do not provide this information will be returned without 
review. 

PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The 
Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) cited 
publicly and officially by a Federal agency in support of an action that has 
the force and effect of law (i.e., a regulation) may be accessed through FOIA.  
It is important for applicants to understand the basic scope of this 
amendment.  NIH has provided guidance at 
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.

Applicants may wish to place data collected under this PA in a public archive, 
which can provide protections for the data and manage the distribution for an 
indefinite period of time.  If so, the application should include a 
description of the archiving plan in the study design and include information 
about this in the budget justification section of the application. In 
addition, applicants should think about how to structure informed consent 
statements and other human subjects procedures given the potential for wider 
use of data collected under this award.

URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals 
for NIH funding must be self-contained within specified page limitations. 
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) 
should not be used to provide information necessary to the review because 
reviewers are under no obligation to view the Internet sites.   Furthermore, 
we caution reviewers that their anonymity may be compromised when they 
directly access an Internet site.

HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving 
the health promotion and disease prevention objectives of "Healthy People 
2010," a PHS-led national activity for setting priority areas. This RFA is 
related to one or more of the priority areas. Potential applicants may obtain 
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.

AUTHORITY AND REGULATIONS: This program is described in the Catalog of Federal 
Domestic Assistance No. 93.273, and is not subject to the intergovernmental 
review requirements of Executive Order 12372 or Health Systems Agency review.  
Awards are made under authorization of Sections 301 and 405 of the Public 
Health Service Act as amended (42 USC 241 and 284) and administered under NIH 
grants policies described at http://grants.nih.gov/grants/policy/policy.htm  
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. 

The PHS strongly encourages all grant recipients to provide a smoke-free 
workplace and discourage the use of all tobacco products.  In addition, Public 
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
facilities (or in some cases, any portion of a facility) in which regular or 
routine education, library, day care, health care, or early childhood 
development services are provided to children.  This is consistent with the 
PHS mission to protect and advance the physical and mental health of the 
American people.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files.